Factors predictive of PFS (univariate analysis)
| . | 4-year PFS . | |||
|---|---|---|---|---|
| HR . | 95% HR confidence limits . | P . | ||
| Low . | High . | |||
| Baseline clinical factors | ||||
| Age (continuous) | 0.99 | 0.96 | 1.03 | .75 |
| Sex (male vs female) | 0.35 | 0.12 | 1.08 | .06 |
| B symptoms (yes vs no) | 2.47 | 0.75 | 8.16 | .13 |
| BMI (median) | 1.00 | 0.86 | 1.16 | .99 |
| ECOG performance status (2-4 vs 0-1) | 1.40 | 0.42 | 4.70 | .58 |
| Hemoglobin < 10.5 g/dL (no vs yes) | 0.79 | 0.24 | 2.61 | .70 |
| LDH (creased vs normal) | 1.71 | 0.48 | 6.16 | .40 |
| ESR (increased vs normal) | 1.77 | 0.16 | 19.63 | .63 |
| Albumin < 4.0 g/dL (yes vs no) | 5.06 | 1.11 | 23.19 | .03 |
| Primary mediastinal disease (yes vs no) | 0.42 | 0.14 | 1.26 | .12 |
| Bulky disease (yes vs no) | 0.33 | 0.07 | 1.53 | .15 |
| Stage at diagnosis (1-2 vs 3-4) | 0.80 | 0.25 | 2.63 | .72 |
| Prognostic score, IPI (continuous) | 1.28 | 0.63 | 2.61 | .49 |
| Prognostic score, IPS (continuous) | 1.49 | 0.65 | 3.42 | .34 |
| Treatment factors | ||||
| Rituximab (yes vs no) | 0.36 | 0.12 | 1.13 | .08 |
| ABVD (yes vs no) | 2.72 | 0.88 | 8.42 | .08 |
| CHOP (yes vs no) | 0.22 | 0.02 | 0.53 | .008 |
| EPOCH (yes vs no) | 6.55 | 1.28 | 33.45 | .02 |
| Consolidative radiotherapy (yes vs no) | 0.36 | 0.12 | 1.14 | .08 |
| . | 4-year PFS . | |||
|---|---|---|---|---|
| HR . | 95% HR confidence limits . | P . | ||
| Low . | High . | |||
| Baseline clinical factors | ||||
| Age (continuous) | 0.99 | 0.96 | 1.03 | .75 |
| Sex (male vs female) | 0.35 | 0.12 | 1.08 | .06 |
| B symptoms (yes vs no) | 2.47 | 0.75 | 8.16 | .13 |
| BMI (median) | 1.00 | 0.86 | 1.16 | .99 |
| ECOG performance status (2-4 vs 0-1) | 1.40 | 0.42 | 4.70 | .58 |
| Hemoglobin < 10.5 g/dL (no vs yes) | 0.79 | 0.24 | 2.61 | .70 |
| LDH (creased vs normal) | 1.71 | 0.48 | 6.16 | .40 |
| ESR (increased vs normal) | 1.77 | 0.16 | 19.63 | .63 |
| Albumin < 4.0 g/dL (yes vs no) | 5.06 | 1.11 | 23.19 | .03 |
| Primary mediastinal disease (yes vs no) | 0.42 | 0.14 | 1.26 | .12 |
| Bulky disease (yes vs no) | 0.33 | 0.07 | 1.53 | .15 |
| Stage at diagnosis (1-2 vs 3-4) | 0.80 | 0.25 | 2.63 | .72 |
| Prognostic score, IPI (continuous) | 1.28 | 0.63 | 2.61 | .49 |
| Prognostic score, IPS (continuous) | 1.49 | 0.65 | 3.42 | .34 |
| Treatment factors | ||||
| Rituximab (yes vs no) | 0.36 | 0.12 | 1.13 | .08 |
| ABVD (yes vs no) | 2.72 | 0.88 | 8.42 | .08 |
| CHOP (yes vs no) | 0.22 | 0.02 | 0.53 | .008 |
| EPOCH (yes vs no) | 6.55 | 1.28 | 33.45 | .02 |
| Consolidative radiotherapy (yes vs no) | 0.36 | 0.12 | 1.14 | .08 |
Bold values indicate factors that are statistically significant. The following variables had too few events to provide an accurate estimate for Cox overall survival models: bone marrow involved (yes vs no), creatinine at diagnosis (increased vs normal), more than 1 extranodal site (yes vs no).
ECOG, Eastern Cooperative Oncology Group; ESR, erythrocyte sedimentation rate.